FDA Approval Sought for Subcutaneous Daratumumab in Multiple Myeloma
A supplemental biologics license application has been submitted to the FDA for a new subcutaneous formulation of daratumumab (Darzalex) for the treatment of patients with multiple myeloma.
Source: OncLive